After selling off Tibsovo and entire cancer pipeline, Agios nets first approval for new 'anchor product'
Agios’ long-term plan is starting to come into focus, as the biotech won its first FDA approval since pivoting away from oncology Thursday.
The FDA approved Agios’ mitapivat in a rare blood disorder known as pyruvate kinase deficiency, which manifests as red blood cells being destroyed faster than they can be made. Agios won the OK in adult patients and touted mitapivat, to be branded as Pyrukynd, as the condition’s first approved disease-modifying therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.